

Systematic reviews for the update of the WHO Guideline on country pharmaceutical pricing policies

Core authors:

David Tordrup¹

Rianne van den Ham¹

Christine Leopold¹

Iris Joosse¹

Julie Glanville²

Eleanor Kotas²

Aukje Mantel-Teeuwisse¹

1: Utrecht Centre for Pharmaceutical Policy and Regulation, Utrecht University, Netherlands

2: York Health Economics Consortium, York, United Kingdom

WHO guideline on country pharmaceutical pricing policies, second edition. Web Annex A. Systematic reviews for the update of the WHO Guideline on country pharmaceutical pricing policies

ISBN 978-92-4-001189-2 (electronic version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Web Annex A. Systematic reviews for the update of the WHO Guideline on country pharmaceutical pricing policies. In: WHO guideline on country pharmaceutical pricing policies, second edition. Geneva: World Health Organization; 2020. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

This publication forms part of the WHO guideline entitled *WHO guideline on country pharmaceutical pricing policies, second edition*. It is being made publicly available for transparency purposes and information, in accordance with the *WHO handbook for guideline development*, 2nd edition (2014).

Table of contents

Table of contents	1
Acknowledgements	5
Abbreviations and acronyms	6
1 Background	8
1.1 Objectives	8
1.2 Structure of the report	9
2 Search methodology and results	10
2.1 Introduction	10
2.2 Search strategies	12
2.3 Running the searches and downloading results	21
2.4 Study selection	22
2.5 Eligibility criteria	22
2.6 Data collection and analysis	25
2.7 Risk of bias assessment	25
2.8 Data synthesis and analysis	26
2.9 Overall search results	28
2.9.1 Studies identified and selected	28
2.10 Discussion of search methods and results	31
2.10.1 Strengths and limitations of the search	31
3 Pooled procurement	34
3.1 Background	34
3.2 Results	35
3.2.1 Excluded studies	35
3.2.2 Characteristics of included studies	35
3.2.3 Effect of interventions	41
3.2.3.1 Impact of regional pooled procurement	41
3.2.3.2 Impact of national pooled procurement	44
3.2.3.3 Impact of mixed level pooled procurement	46
3.2.3.4 Impact of international pooled procurement	48
3.3 Authors' conclusions	50
3.3.1 Summary of main results	50
3.3.2 Overall completeness and applicability of evidence	50
3.3.3 Quality of the evidence	50
3.3.4 Agreement/disagreement with other reviews	51

	3.3.5	Authors conclusions: implications for practice; implications for research	51
4		Value based pricing.....	53
	4.1	Background	53
	4.2	Results	54
	4.2.1	Excluded studies	54
	4.2.2	Characteristics of included studies	54
	4.2.3	Effect of interventions	57
	4.2.3.1	Impact of VBP as a general cost control policy	57
	4.2.3.2	Impact of VBP as a disinvestment tool	60
	4.3	Authors' conclusions.....	62
	4.3.1	Summary of main results.....	62
	4.3.2	Overall completeness and applicability of evidence.....	62
	4.3.3	Quality of the evidence	63
	4.3.4	Agreement/disagreement with other reviews	63
	4.3.5	Authors conclusions: implications for practice; implications for research	63
5		Discounts for single source pharmaceuticals	64
	5.1	Background	64
	5.2	Results	65
	5.2.1	Excluded studies	65
	5.2.2	Characteristics of included studies	65
	5.3	Authors' conclusions.....	65
	5.3.1	Agreement/disagreement with other reviews	65
	5.3.2	Authors conclusions: implications for practice; implications for research	65
6		Cost-plus pricing	67
	6.1	Background	67
	6.2	Results	68
	6.3	Authors' conclusions.....	68
	6.3.1	Agreement/disagreement with other reviews	68
	6.3.2	Authors conclusions: implications for practice; implications for research	68
7		Tax exemptions or tax reductions for pharmaceuticals	69
	7.1	Background	69
	7.2	Results	70
	7.2.1	Excluded studies	70
	7.2.2	Characteristics of included studies	70
	7.3	Authors' conclusions.....	70
	7.3.1	Agreement/disagreement with other reviews	70
	7.3.2	Authors conclusions: implications for practice; implications for research	70
8		Promoting the use of quality assured generic and biosimilar medicines	71

	8.1	Background	71
	8.2	Results	72
	8.2.1	Excluded studies	72
	8.2.2	Characteristics of included studies	72
	8.2.3	Effect of interventions	78
	8.2.3.1	Impact of dispensing policies	78
	8.2.3.2	Impact of reimbursement policies	80
	8.2.3.3	Impact of prescribing policies	83
	8.2.3.4	Impact of mixed measures	86
	8.2.3.5	Impact of market entry regulations	88
	8.3	Authors' conclusions	90
	8.3.1	Summary of main findings	90
	8.3.2	Overall completeness and applicability of evidence	90
	8.3.3	Quality of evidence	91
	8.3.4	Agreement/disagreement with other reviews	91
	8.3.5	Authors conclusions: implications for practice; implications for research	91
9		Reference Pricing	93
	9.1	Background	93
	9.2	Results	94
	9.2.1	Excluded studies	94
	9.2.2	Characteristics of included studies	94
	9.2.3	Effect of interventions	104
	9.2.3.1	Impact of generic reference pricing	104
	9.2.3.2	Impact of therapeutic reference pricing	110
	9.2.3.3	Impact of mix generic and therapeutic reference pricing	116
	9.2.3.4	Impact of (generic) price linkage	119
	9.3	Authors' conclusions	124
	9.3.1	Summary of main results	124
	9.3.2	Overall completeness and applicability of evidence	124
	9.3.3	Quality of the evidence	125
	9.3.4	Agreement/disagreement with other reviews	125
	9.3.5	Authors conclusions: implications for practice; implications for research	126
10		Promoting price transparency	128
	10.1	Background	128
	10.2	Results	129
	10.2.1	Excluded studies	129
	10.2.2	Characteristics of included studies	129
	10.2.3	Effect of interventions	131

10.2.3.1	Impact of cost-feedback to prescribers	131
10.2.3.2	Impact of publicly available prices	134
10.3	Authors' conclusions	137
10.3.1	Summary of main results	137
10.3.2	Overall completeness and applicability of evidence	137
10.3.3	Quality of the evidence	137
10.3.4	Agreement/disagreement with other reviews	137
10.3.5	Authors conclusions: implications for practice; implications for research	138
11	Mark-up regulation across the pharmaceutical supply and distribution chain	139
11.1	Background	139
11.2	Results	139
11.2.1	Excluded studies	139
11.2.2	Characteristics of included studies	140
11.2.3	Effect of interventions	146
11.2.3.1	Impact of price caps	146
11.2.3.2	Impact of mark-up thresholds	151
11.3	Authors' conclusions	156
11.3.1	Summary of main results	156
11.3.2	Overall completeness and applicability of evidence	156
11.3.3	Quality of the evidence	156
11.3.4	Agreement/disagreement with other reviews	157
11.3.5	Authors conclusions: implications for practice; implications for research	157
12	Tendering and negotiation	159
12.1	Background	159
12.2	Results	160
12.2.1	Excluded studies	160
12.2.2	Characteristics of included studies	160
12.2.3	Effect of interventions	161
12.3	Authors' conclusions	163
12.3.1	Summary of main results	163
12.3.2	Overall completeness and applicability of evidence	163
12.3.3	Quality of the evidence	163
12.3.4	Agreement/disagreement with other reviews	163
12.3.5	Authors conclusions: implications for practice; implications for research	163
13	References	164
	Appendix A: Search Strategies	186
	Appendix B: Excluded studies	283

Acknowledgements

The authors are grateful for the review and suggestions of colleagues associated with the Guideline Development Group and WHO: Fatima Suleman, Lisa Bero, Sabine Vogler, Kiu Tay-Teo. Colleagues at York Health Economics Consortium (YHEC) who contributed to the extensive search process include Ross Birtles, Mick Arber, Chris Bartlett, James Mahon. Additionally, Deborah Toppenberg-Pejcic assisted with the screening of grey literature at country level. The authors are grateful to Prof. Zaheer Babar, Prof. Jaime Espin and Dr. Kalipso Chalkidou for constructive remarks on earlier drafts of the technical topics.

Abbreviations and acronyms

ACE	Angiotensin-converting enzyme
ACEI	Angiotensin-converting-enzyme inhibitors
AMNOG	Arzneimittelmarkt-Neuordnungsgesetz
ARV	Antiretroviral
ASL	Aziende Sanitarie Locali (local hospitals)
ATC	Anatomical Therapeutic Chemicals
CBA	Controlled Before-After
CDSR	Cochrane Database of Systematic Reviews
CEA	Cost-Effectiveness Analysis
CHC	Community Health Centre
CPB	Central Purchasing Bodies
CRD	Centre for Reviews and Dissemination
DARE	Database of Abstracts of Reviews of Effects
DDD	Defined Daily Dose
DID	Difference-in-Differences
DPCO	Drug Price Control Order
DRG	Diagnosis Related Group
DRP	Drug list Rearrangement Project
EPOC	Cochrane Effective Practice and Organisation of Care
ERP	External Reference Pricing
EU	European Union
GDP	Gross Domestic Product
GDR	Generic Dispensing Ratio
GFATM	Global Fund to Fight AIDS, Tuberculosis and Malaria
GPRM	Global Price Reporting Mechanism
GRADE	Grading of Recommendations, Assessment, Development and Evaluation
GRP	Generic Reference Pricing
HAI	Health Action International
HHI	Herfindahl-Hirschman Index
HIV	Human Immunodeficiency Virus
HMIC	Healthcare Management Information Consortium
HTA	Health Technology Assessment

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24353

